After mpox outbreak, Africa is under the threat of yet another virus outbreak, this is the Marburg virus outbreak in Rwanda. So far, six people have died from the outbreak, confirmed the health minister. Most victims were the healthcare workers in the hospital's intensive care unit. As per reports, 20 cases have been identified since the outbreak was confirmed on Friday.

What Is Marbug Virus?

With the fatality rate of 8% it is the same virus family as Ebola. The main carrier is from fruit bats which spreads to humans then through the contact of bodily fluids of infected individuals, it spreads to others.

Common Signs And Symptoms

The common signs and symptoms of the Marburg virus include fever, pain, diarrhoea, vomiting and in the case of extreme blood loss, death too can happen.

So far, there is no specific treatment or vaccine for the virus. However, treatments like drugs and immune therapy are being developed as per the World Health Organisation (WHO).

Call Of Action

Rwanda says that it has intensified its contact tracing, surveillance and testing to contain the spread. It has also tracked about 300 people who had come into contact with individuals affected by the Marburg virus.

The health minister has urged people to stay vigilant and avoid any physical contact and to wash their hands with clean water, soap or sanitiser and report any suspected case.

As of now, most of the cases have spread to the capital in Kigali. In light of this, the US Embassy in the city has advised its employees to work remotely for the next week.

This is the first time Rwanda has confirmed for Marburg cases, before this, in 2023, Tanzania confirmed the outbreak, whereas three people had died of this in Uganda in 2017.

History Of Marburg

As per WHO, this virus kills half of the people it infects. In the previous outbreaks, it has killed between 24% to 88% of the patients.

The virus was first detected in 1976 after 31 people were infected, out of which 7 died in simultaneous outbreak in Marburg and Frankfurt in Germany, and Belgrade in Serbia.

The source was traced to African green monkeys who were imported from Uganda. However, other animals too are linked to the virus spread, including bats.

In the past, the virus outbreaks have happened in countries like Equatorial Guinea, Ghana, the Democratic Republic of the Congo, Kenya, South Africa, Uganda, and Zimbabwe. In 2005, this virus killed 300 people in Angola.

However, for the rest of the world, only two people have died from the virus in the rest of the world, with one of them being in Europe, and the other in the US. These both have been on expeditions to caves in Uganda.

Alkem Laboratories today announced the launch of semaglutide in single-shot pre-filled syringes in multiple dose strengths, with prices starting at Rs 350.

The company, in a statement, said it is the first in India to introduce semaglutide in a single-shot pre-filled syringe format for the management of Type 2 diabetes mellitus and obesity as an adjunct to diet and exercise.

The ready-to-use format will expand treatment options for patients while lowering entry barriers through affordable pricing.

“Semaglutide has the potential to change how we manage metabolic disorders. With the launch of our pre-filled syringes, we are widening the choice available to doctors and patients, alongside the pen options we have already introduced,” said Dr. Vikas Gupta, Chief Executive Officer of Alkem Laboratories.

“In India, where we are seeing a continuous rise in disease burden, offering multiple, practical drug delivery formats is an important step in helping more patients start and stay on the therapy,” he added.

Alkem noted that it has received approval from the Drugs Controller General of India (DCGI) to manufacture and market semaglutide pre-filled syringes.

Also read: India To Tighten Regulation For Semaglutide, Other GLP-1 Drugs

The launch follows Alkem’s introduction of semaglutide in pre-filled disposable and reusable injection pen formats in the Indian market in March 2026. The company has also secured regulatory approval for semaglutide vials, which it plans to launch soon.

Meanwhile, domestic peers such as Torrent Pharma and Dr Reddy’s have also introduced non-infringing tablets, with Lupin, Sun Pharma and several others expected to follow suit.

Semaglutide: Risks Vs Benefits

In people with type 2 diabetes, Harvard Health noted that the body's cells are resistant to the effects of insulin and the body does not produce enough insulin, or both. This is when GLP-1 agonists stimulate the pancreas to release insulin and suppress the release of another hormone called glucagon.

These drugs also act in the brain to reduce hunger and act on the stomach to delay emptying, so you feel full for a longer time. These effects can lead to weight loss, which can be an important part of managing diabetes.

Notably, semaglutide is not just a glucose-lowering drug, it improves weight and has proven cardiovascular, liver, and renal benefits.

Read More: Pairing Ozempic With Exercise Is Beneficial For Your Muscles, Study Finds

Wider availability could therefore help reduce long-term complications such as heart disease and kidney failure. If used appropriately, this could indeed be a major step forward in total metabolic care, the experts said.

“The increasing affordability of GLP-1 receptor agonists is a double-edged development. On one hand, it significantly improves access for patients with obesity, type 2 diabetes, and high cardiovascular risk, conditions that are highly prevalent in India. These drugs have demonstrated meaningful benefits in weight reduction, glycemic control, and even cardiovascular risk reduction, which could translate into long-term public health gains,” Dr Vivek Bindal, Senior Director & Head, Bariatric and Robotic Surgery, at Max Healthcare, told HealthandMe.

Western Australia is seeing a steady rise in mpox infections, with seven cases reported during the past week, according to the Department of Health.

In a statement, the department said that 22 mpox cases have been reported in Western Australia so far in 2026. The figure marks a significant increase compared with 2025, when 27 cases were recorded throughout the entire year, and 2024, which saw 23 cases.

Health Authorities Urge Vigilance

Health officials have advised the public to remain alert for symptoms of the disease. Public health investigations and contact tracing are also underway to prevent further transmission.

Nineteen of the cases were acquired locally, while three were linked to overseas travel. Two of the cases reported this year were in cisgender women, a first for Western Australia. Another two cases were reported in heterosexual men, the officials said.

Dr. Paul Armstrong, Director of Communicable Disease Control, said the department was working closely with affected individuals and their contacts to help prevent further spread of the virus.

“Mpox is a viral infection that typically causes mild illness, including fever, headache, muscle aches, swollen lymph nodes, or fatigue, followed by a skin rash or lesions,” Dr Armstrong said.

“It does not spread easily between people and is mainly transmitted through very close or intimate contact with an infected person.

“While anyone can contract mpox, recent cases in Australia and internationally have occurred more commonly among sexually active gay, bisexual, and other men who have sex with men,” the expert said.

Vaccination Recommended For High-Risk Groups

Dr Armstrong encouraged eligible people in Western Australia to consider vaccination, particularly before travelling to countries experiencing mpox transmission.

“The mpox vaccine is available through sexual health clinics and participating GPs for people at higher risk of exposure,” he said.

“Two doses are recommended for optimal protection, and vaccination can reduce the risk of infection and severe disease.”

Anyone concerned they may have been exposed to mpox, or experiencing symptoms consistent with the infection, should call ahead before attending a healthcare facility so appropriate precautions can be arranged.

What Is Mpox?

Mpox is a viral disease caused by the monkeypox virus, which belongs to the same family of viruses as smallpox.

The virus spreads through close physical contact with an infected person, contaminated materials, or infected animals.

The illness generally lasts between two and four weeks and resolves on its own. However, severe disease can occur, particularly in children, pregnant women, and people with weakened immune systems.

Complications may include secondary infections, respiratory problems, and, in rare cases, death.

How Can Mpox Be Prevented?

Also read: India Makes Significant Progress In Maternal Care, Nutrition And Child Immunization: NFHS-6

Vaccination: Vaccines originally developed for smallpox can help protect against mpox. Health authorities recommend vaccination for people at higher risk of exposure.

Good Hygiene: Regular handwashing, avoiding close contact with infected individuals and contaminated materials, and following public health guidance can reduce the risk of infection.

Early Detection And Monitoring: People who develop symptoms or believe they may have been exposed should seek medical advice promptly. Laboratory testing, including RT-PCR, is available to confirm infection and support timely treatment and contact tracing.

Once marketed as a safer alternative to cigarettes, research now shows that vapes carry serious health risks, including lung damage, meningitis, and cancer.

Unlike cigarettes, these devices are often ready to use, brightly colored, require little effort to activate, and appear more like toys than a harmful product. But due to its addictive flavor, people end up consuming more tobacco than those who smoke unflavored ones.

Globally, 33 countries ban the sale of electronic nicotine delivery systems (ENDS), a category that includes e-cigarettes and vapes, according to a 2023 World Health Organization (WHO) report. Another 87 countries regulate the sale of ENDS.

Malaysia has become the latest country to intensify efforts to curb vaping, with the Health Ministry launching a major crackdown on the online promotion and sale of smoking and vape products under Ops Selamat PaPa.

In a statement, the ministry said the operation aims to target the manufacturing, distribution, and sale of all types of smoking products, and protect the younger generation.

“Following its increasing and widespread use, this operation was launched to protect the younger generation from the dangers of smoking products, including electronic cigarettes and vaping,” the statement said.

“We take the complaints raised on social media over online advertising and sales of vape products suspected of violating the Control of Smoking Products for Public Health Act 2024 (Act 852) seriously," it added.

The Health Ministry said it had investigated 10 websites following the complaints and requested that the Malaysian Communications and Multimedia Commission block four of them under the provisions of the Communications and Multimedia Act 1998 (Act 588). The remaining six websites are still under investigation, The Straits Times reported.

According to the ministry, as of April 30, a total of 34,903 enforcement operations had been carried out following inspections at 683,704 premises nationwide.

“We constantly monitor online advertising and promotion of tobacco products, including the sale of vapes. We wish to stress that there will be no compromise for those who violate laws,” the ministry said.

UK Parliament Bans Cigarettes and Vapes

The UK Parliament has passed a “landmark bill” to ban smoking among children who were born on or after 1 January 2009.

Under the new Tobacco and Vapes Bill, people aged 17 or younger face a lifelong ban on buying cigarettes. This includes a ban on selling vapes to anyone under 18 and selling them through vending machines.

Vaping A Major Threat Among Under-5s in the US

Vaping has been a serious concern in the United States, with New York Attorney General Letitia James in 2025 filing a lawsuit against e-cigarette manufacturers and distributors.

The lawsuit accused the companies of fueling a youth vaping crisis, alleging that these companies that manufacture vapes, especially with flavors, have misled consumers about the safety of their products while deliberately targeting young people through deceptive marketing.

An April 2026 study, published in JAMA Network Open, for the first time assessed trends in young children's nicotine exposures across all types of products.

Shockingly, electronic cigarette-related incidents increased 243 percent over the past eight years in young children, especially among those under five years of age, said researchers from the Rutgers New Jersey Medical School.

Vaping has also become a more common form of tobacco use among American middle and high school students.

As per the US Centers for Disease Control and Prevention (CDC), nearly 1.6 million students used e-cigarettes in 2024, with 87.6 percent of them opting for a flavored product.